Cargando…

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries

BACKGROUND: A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong...

Descripción completa

Detalles Bibliográficos
Autores principales: Garland, S M, Pitisuttithum, P, Ngan, H Y S, Cho, C -H, Lee, C -Y, Chen, C -A, Yang, Y C, Chu, T -Y, Twu, N -F, Samakoses, R, Takeuchi, Y, Cheung, T H, Kim, S C, Huang, L -M, Kim, B -G, Kim, Y -T, Kim, K -H, Song, Y -S, Lalwani, S, Kang, J -H, Sakamoto, M, Ryu, H -S, Bhatla, N, Yoshikawa, H, Ellison, M C, Han, S R, Moeller, E, Murata, S, Ritter, M, Sawata, M, Shields, C, Walia, A, Perez, G, Luxembourg, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989602/
https://www.ncbi.nlm.nih.gov/pubmed/29767739
http://dx.doi.org/10.1093/infdis/jiy133